Skip to main content

Relmada Therapeutics, Inc 8-K, filed Nov 16, 2026

Relmada Therapeutics, Inc. (RLMD)

8-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 8-K

Relmada Therapeutics, Inc filed this 8-K on November 16, 2026.

Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology on November 16, 2026. He will lead clinical development across its pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits